Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegloticase in Refractory Gout
NCT00111657Phase 2Completed
- Start
- Dec 2004
- Primary completion
- Jul 2009
- Countries
- 1
01
Overview
Phase 2, open-label trial of pegloticase in gout. Primary endpoint: Reduction in Plasma Uric Acid to Less Than 6 mg/dL at Day 105. Started Dec 2004; status: completed.
02
Drugs
pegloticase
03
Conditions
gout
Beyond the preview
Go deeper on NCT00111657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111657.